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Abstract
The therapeutic benefit of B cell depletion in patients with rheumatoid arthritis has provided proof of concept that B cells
are relevant for the pathogenesis of arthritis. It remains unknown which B cell effector functions contribute to the induction
or chronification of arthritis. We studied the clinical and immunological effects of B cell depletion in glucose-6-phosphate
isomerase-induced arthritis. We targeted CD22 to deplete B cells. Mice were depleted of B cells before or after immunization
with glucose-6-phosphate isomerase (G6PI). The clinical and histological effects were studied. G6PI-specific antibody
responses were measured by ELISA. G6PI-specific T helper (Th) cell responses were assayed by polychromatic flow
cytometry. B cell depletion prior to G6PI-immunization prevented arthritis. B cell depletion after immunization ameliorated
arthritis, whereas B cell depletion in arthritic mice was ineffective. Transfer of antibodies from arthritic mice into B cell
depleted recipients did not reconstitute arthritis. B cell depleted mice harbored much fewer G6PI-specific Th cells than
control animals. B cell depletion prevents but does not cure G6PI-induced arthritis. Arthritis prevention upon B cell
depletion is associated with a drastic reduction in the number of G6PI-specific effector Th cells.
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Introduction
The therapeutic success of the B cell–depleting drug Rituximab
(anti-CD20 antibody) in treating patients with rheumatoid arthritis
(RA) has induced intensified interest in how B cells contribute to
the pathogenesis of autoimmune diseases. B cells can produce
autoantibodies and function as antigen-presenting cells (APC),
which can profoundly influence T-helper (Th) cell proliferation
and effector functions. They produce cytokines and regulate
lymphoid tissue architecture and neogenesis. Which of these
functions are relevant for RA and how B cell depletion exerts its
therapeutic effect is currently unclear.
The identification of the mechanism by which B cells contribute
to the induction or propagation of chronic synovitis in RA is
severely hampered by the fact that analysis of the effects of B cell
depletion is often restricted to peripheral blood, which contains
only a minority of the total B cell population (less than 2%, [1]).
For mechanistic studies, preclinical arthritis models are clearly
needed. B cell depletion studies have been performed in collagen-
induced arthritis (CIA) [2,3], proteoglycan-induced arthritis [4]
and arthritic K/BxN mice [5]. We chose to examine the effect of B
cell depletion in glucose-6-phosphate isomerase (G6PI)-induced
arthritis. Upon one single immunization with G6PI in adjuvant,
peripheral symmetric polyarthritis develops with high incidence in
genetically susceptible strains of mice [6,7]. G6PI is also the target
autoantigen in the transgenic K/BxN mice, which develop high
titers of anti-G6PI specific autoantibodies [8,9]. These autoanti-
bodies are arthritogenic in the K/BxN transfer model, where
transfer of serum or G6PI-specific mAbs generated from the
transgenic K/BxN mice is sufficient to induce the disease in
recipient mice [8,10]. In arthritis induced by immunization of
non-transgenic mice with G6PI in CFA, the role of B cells and/or
autoantibodies is much less clear. We have shown that mice
lacking mature B cells are fully resistant against G6PI-induced
arthritis [7]; in mice lacking the FccR common gamma chain
G6PI-induced arthritis occurs at a very low incidence and strongly
reduced severity, whereas G6PI-induced arthritis is more severe
and chronic in mice lacking the inhibitory FccRIIB [6]. However,
in contrast to the K/BxN model and collagen-induced arthritis
(CIA), G6PI-induced arthritis can not be transferred into
syngeneic recipients by adoptive transfer of serum from diseased
animals [6]. Thus, B cells and antibodies are necessary but not
sufficient for the pathogenesis of G6PI-induced arthritis.
To deplete B cells we targeted CD22, a lectin-like member of
the Ig superfamily, which is expressed exclusively by all mature B
cells [11]. Antibodies targeting CD22 are available for human use
as well, and are currently investigated in clinical trials. To target
CD22
+ cells we used an anti-CD22 monoclonal antibody
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efficiently depletes mature B cells in mice [2]. CD22-cal has been
extensively characterized and used in animal models of arthritis,
infection and type 1 diabetes [2,12].
Materials and Methods
Mice induction of arthritis and treatment
Female SJL/J mice were bred and maintained in our specific-
pathogen free animal facility. All experiments were approved by
the appropriate governmental authority (Thu ¨ringer Landesamt fu ¨r
Lebensmittelsicherheit und Verbraucherschutz; registration num-
bers 02-005/06 and 02-024/04) and conducted in accordance
with institutional and state guidelines. Recombinant human G6PI
was prepared as previously described [6]. Six- to 12-wk-old mice
were immunized subcutaneously at the base of the tail with 400 mg
G6PI emulsified in 200 ml CFA (Sigma-Aldrich, Taufkirchen,
Germany). Animals were scored for clinical signs of arthritis
(erythema, swelling, ankylosis) on a 0–3 point scale for each paw,
giving a total maximum score of 12. Histopathological assessment
was performed as described before [6] by a pathologist (L.M.) who
was blinded with respect to the experimental groups. For depletion
of B cells, mice were treated with an immunotoxin consisting of
anti-mouse CD22 mAb (Cy34.1) conjugated to N-acetyl-c-
calicheamicin dimethyl acid (CD22-cal) as described [2]. At the
indicated time points mice were intraperitoneally injected with
150 mg CD22-cal (containing ,3 mg calicheamicin) per injection.
For serum transfer studies, 250 ml pooled sera from either arthritic
(d15–20 after immunization) or naı ¨ve mice were injected
intraperitoneally at days 9 and 11 after immunization.
Anti-G6PI-Ig ELISA
The amount of G6PI-specific antibodies were measured by
ELISA in serially diluted serum samples as previously described
[6].
Flow cytometry
For analysis of B cell depletion we isolated lymph nodes, spleens,
peripheral blood and bone marrow (from femurs) at the indicated
time points. After preparation of a single cell suspension and lysis
of erythrocytes, cells were stained with fluorochrome-conjugated
anti-bodies against CD3, CD11b and CD19 for 20 minutes on ice.
After washing, cells were acquired using a BD LSRII flow
cytometer. Data were analyzed using FlowJo 8.1.1 (Treestar Inc.,
Ashland, Oregon).
For analysis of G6PI-specific T cells, cells from draining lymph
nodes (inguinal, axillary, paraaortic; 1610
7/ml) were cultured for
6 hours with 20 mg/ml G6PI or left unstimulated. For the last
4 hours, Brefeldin A (Sigma) at 5 mg/ml was added to all samples.
At the end of the restimulation period, cells were washed and
incubated with the fixable amine-reactive Aqua viability stain
(Invitrogen) for 30 minutes on ice, fixed with 2% paraformaldehyd
in PBS and permeabilized with 0.5% Saponin/0.5% BSA/
0.02%NaN3 in PBS. Non-specific binding of antibodies was
blocked by preincubation of the cells with anti-CD16/32 (2.4G2)
and rat IgG (both at 5 mg/ml) for 8 minutes, followed by staining
with fluorochrome-conjugated monoclonal antibodies against
CD4, CD154, TNF-a, RANKL, IL-2, IL-17 and IFN-c (all from
eBiosciences or Miltenyi Biotech). At least 2.5 million events were
acquired. Gates for CD154 were set using unstimulated control
samples and gates for cytokine+ cells were set using fluorescence-
minus-one controls for the respective cytokine.
For supplementation of antigen-presenting cells, single cell
suspension of splenocytes from immunized mice were labeled with
CFSE (5 mM for 3 minutes in ice). After washing with PBS, cells
were adjusted to 1610
7/ml and mixed in a 1:1 ratio with the
lymph node cells of either control or anti-CD22-cal treated mice.
This mixture was pulsed with antigen, stained and analyzed
exactly as described above.
Statistics
Data were analyzed using the non-parametric Man-Whitney U
test with SPSS 15.0 (SPSS Inc., Chicago, USA) unless otherwise
indicated. Graphs were generated using SigmaPlot 10.0 (Systat
Software Inc, Chicago, USA). Data is presented as means 6
standard error of mean (SEM) unless otherwise indicated.
Results
SJL mice are susceptible to G6PI-induced arthritis
To investigate the role of B cells in G6PI-induced arthritis at
different disease stages, we wished to use a B cell depleting
immunoconjugate (anti-CD22 mAb conjugated to chalicheamicin,
referred hereafter to as CD22-cal). G6PI-induced arthritis is
usually induced in DBA/1 mice [6,7] which do not express the
Lyb-8.2 alloantigen [13]. The Cy34.1 antibody used in these
studies reacts with CD22 in strains expressing the Lyb-8.2
alloantigen, such as C57BL/6 or SJL/J. We, therefore, examined
SJL/J mice for their susceptibility to G6PI-induced arthritis.
Following immunization with one single dose of G6PI/CFA
subcutaneously on day 0, SJL/J mice developed arthritis with the
same cumulative incidence (more than 90%) and rapid onset as
DBA/1 mice. Maximal clinical scores were reached somewhat
later (. day 21) in SJL/J than in DBA/1 mice (, day 21) and
G6PI-induced arthritis was more chronic in SJL/J compared to
DBA/1 mice (Fig. 1A).
Clinical signs of arthritis were also confirmed by histology:
Fig. 1B shows a very severe active arthritis with a dense infiltrate of
neutrophil granulocytes, accompanied by lymphocytes, plasma
cells, macrophages and activated fibroblasts in the synovial
membrane. This tissue invades and destroys the joint cartilage
and infiltrates deep into the underlying bone. The histological
picture is similar to the infiltrates seen in DBA/1 mice, as
previously described [6].
SJL/J mice generated G6PI-specific T cell- and antibody
responses that were similar to those in DBA/1 mice regarding,
quantity, quality and kinetics (data not shown).
CD22-cal causes prolonged B cell depletion
To assess the extent and duration of B cell depletion in G6PI-
immunized mice, SJL/J mice were treated with 150 mg CD22-cal
at days 26 and 21 before immunization and immunized with
G6PI at day 0. Spleens, lymph nodes, blood and bone marrow
were collected at different time points after immunization and the
frequency of CD19
+ B cells and CD3
+ T cells analyzed by flow
cytometry. In peripheral blood of CD22-cal treated mice, CD19
+
B cells were massively depleted over a long time. The anti-CD22-
cal treated animals harbored only 4.62% (day 0); 6.71% (day 7);
27,1% (day 14); 17.86% (day 21) or 17.59% (day 28) of the
peripheral blood B cells in control mice.
Lymph nodes and spleens in CD22-cal treated mice contained
fewer cells compared to controls at all time points examined
(between 47 and 74% of the controls; Fig. 2, left). The total
number of bone marrow cells was also reduced in these mice. As
expected, B cells were hardly detectable in the secondary
lymphatic organs of CD22-cal treated mice within the first week
after G6PI-immunisation, they started to recover slowly at
approximately 2 weeks after the immunization but their numbers
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PLoS ONE | www.plosone.org 2 September 2011 | Volume 6 | Issue 9 | e24718Figure 1. SJL/J mice are susceptible to G6PI-induced arthritis. A) Age matched female DBA/1 and SJL/J mice were immunized with 400 mg
G6PI in complete Freund’s adjuvant and scored for clinical arthritis severity as described in Materials and Methods. B) Histological features of G6PI-
induced arthritis in SJL/J mice. The overview (left, 625) shows the severe destruction of the joint. Cartilage is completely missing, and parts of the
underlying bone are infiltrated as well (center, 6100). The inflammatory infiltrate consist mainly of neutrophil granulocytes, but lymphocytes and
plasma cells are clearly visible (right,6400). The underlying pannus consists of activated fibroblasts and is covered by an enlarged synovial lining. In
the synovial space, a putrid exudate with numerous granulocytes is found (all figures, H&E staining).
doi:10.1371/journal.pone.0024718.g001
Figure 2. B cell depletion in CD22-cal treated mice. Mice were treated with CD22-cal at days 26 and 21 and were immunized with 400 mg
G6PI in complete Freund’s adjuvant. Control mice were immunized but otherwise left untreated. Lymph nodes (LN), spleens and bone marrow were
isolated, counted and analyzed for the percentage of CD19
+ B and CD3
+ T lymphocytes. Shown are the total number cells harvested (left) or the total
number of B- (middle) or T-lymphocytes (right) in the various organs. Data are representative for at least three mice per time point.
doi:10.1371/journal.pone.0024718.g002
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observation period. (Fig. 2, middle).
We also noted a slight decrease in the number of CD3
+ T cells
in spleens and lymph nodes of CD22-cal treated animals (Fig. 2,
right). Although CD22-cal specifically depletes B cells, it is
important to note here that the reduced B cell numbers do not
fully explain the observed reduction in total cell numbers
recovered from spleens and lymph nodes. For instance, the
number of CD19
+ B cells in lymph nodes from day 7 fell from
,8.5610
6 to 0.2610
6 whereas the total cell number was reduced
from 43610
6 to 20610
6. Taken together, our data show that
treatment with CD22-cal leads to long lasting depletion of B cells
in lymph nodes, spleen and blood and suggest that this B cell
depletion indirectly affects the cellular composition of the
secondary lymphoid organs in response to immunization as shown
here by the reduced numbers of CD3
+ T cells (Fig. 2, right).
Prophylactic B cell depletion protects from arthritis
induction
To assess the effect of B cell depletion on arthritis, mice
received two injections of 150 mgC D 2 2 - c a le i t h e ra td a y s26
and 21 or days 3 and 8 relative to immunization with G6PI.
Mice treated prior to immunization showed a markedly delayed
disease onset, the cumulative incidence reached only 50% and
the clinical severity remained lower than in the control mice.
When CD22-cal was injected at days 3 and 8 after
immunization, arthritis incidence was still reduced to approx-
imately 50% of controls (Fig. 3 A, left). Clinical arthritis scores
of those mice that did develop disease after late CD22-cal
treatment were lower than those of the control mice but higher
than those of the mice, which had received prophylactic
treatment (Fig. 3 A, right). We confirmed these findings by
semiquantitative analysis of the histopathological changes (Fig. 3
B). Signs of acute and chronic inflammation as well as joint
destruction were lower in either group of treated mice than in
controls. We next asked if B cell depletion could also cure
established G6PI-induced arthritis. As shown in Fig. 3 C, when
the mice were treated at the peak of clinical disease (days 15
and 20 after immunization), anti-CD22-cal treatment was
ineffective. Taken together, our data show that the critical role
of B cells for pathogenesis of G6PI-induced arthritis is restricted
to early phases of disease development.
Lower anti-G6PI-specific Ig-levels in CD22-cal treated
mice
Antibodies against G6PI were almost absent in CD22-cal
treated animals 7d after immunization (Fig. 4). At later time points
(day 21 and 28), sera from CD22-cal treated mice contained anti-
G6PI Igs of all isotypes, albeit at slightly lower levels compared to
control animals (Fig. 4). Interestingly, the development of these
titers occurred at a time point at which the numbers of B cells still
were profoundly reduced (Fig. 2).
Figure 3. G6PI-induced arthritis in CD22-cal treated mice. SJL/J mice were immunized with 400 mg G6PI in complete Freund’s adjuvant and
treated at the indicated time points with CD22-cal. Mice were scored for clinical signs of arthritis. A) Treatment with CD22-cal before (day 26, day 21)
immunization or in early preclinical stage (day 3, day 11) delay the onset and reduces the incidence of arthritis, compared to untreated controls (Left).
Furthermore, prophylactic CD22-cal treatment strongly reduces the clinical severity of arthritis which still develop disease; this effect was much lower
in mice treated in the induction phase (right). B) H&E stained sections were scored for the extend of acute (infiltration of neutrophil granulocytes) and
chronic (infiltration of mononuclear cells) inflammation as well as joint destruction (cartilage and bone erosions) in a semiquantitative manner. For
each parameter a maximum score of 4 could be reached. Shown are the sums score of all paws of individual at day 36 after immunization. C) Clinical
score of mice that were treated with CD22-cal as described above at days 15 and 20 after immunization.
doi:10.1371/journal.pone.0024718.g003
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arthritis development
Approximately 50% of the animals treated with CD22-cal at
days -6 and -1 before immunization still developed arthritis, albeit
with a delayed onset and reduced severity (Fig. 3 A). We
hypothesized that this delayed disease induction might be due to
the lack of G6PI-specific immunoglobulins at early time points. To
test this we reconstituted B cell depleted mice with pooled sera
from or naı ¨ve or arthritic mice at days 9 and 11 after
immunization. Neither treatment could restore clinical arthritis
scores in B cell depleted mice to the level in control mice.
Furthermore, there was no difference between recipients of serum
from arthritic or naı ¨ve mice (Fig. 5). These findings strongly argue
against a lack of G6PI-specific immunoglobulins as the sole
explanation for the beneficial effect of B cell depletion in G6PI-
induced arthritis.
Massively reduced G6PI-specific T cell response in B cell
depleted mice
Th cells are strictly required both in the induction- and the
effector-phase of G6PI-induced arthritis [6]. We used multipa-
rameter flow cytometry to compare the frequency and cytokine
production of G6PI-specific T cells at day 9 after G6PI-
immunization. Lymph node cells were briefly restimulated with
G6PI, fixed and stained for CD154 and various cytokines for
detection of antigen-specific T cells [14,15,16,17]. Compared to
the controls, the total number of CD154
+ G6PI-specific Th cells
was approximately 10-fold reduced in CD22-cal treated mice
Figure 4. G6PI-specific Ig-levels in CD22-cal treated mice. Mice were treated with CD22-cal as in Fig. 2. Sera of mice were harvested at the
indicated time points. Serially diluted sera (1/100, 1/400, 1/1600, 1/6.400, 1/25.600, 1/102.400, 1/409.600) were tested by ELISA for the presence of
anti-G6PI-Ig’s of the indicated isotypes. Shown are the optical densities, corrected for background. The data represent three indiviual mice per group
and time point.
doi:10.1371/journal.pone.0024718.g004
Figure 5. Serum transfer in CD22-cal treated mice. CD22-cal
treated mice (day 26, day 21) or untreated mice were immunized with
G6PI. At day 9 and 11, CD22-cal treated mice received 2 injections of
pooled serum from either arthritic or naı ¨ve SJL/J mice. Shown is the
clinical arthritis score from all mice per group (n=8 per group).
doi:10.1371/journal.pone.0024718.g005
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e24718Figure 6. G6PI-specificTh cell response in CD22-cal treated mice. Mice were treated with CD22-cal at days 26 and 21 and were immunized
with 400 mg G6PI in complete Freund’s adjuvant. Control were immunized but otherwise left untreated. At day 9 after immunization, cells from the
draining lymph nodes (inguinal, axillary, paraaortic) were restimulated with G6PI, fixed and stained for flow cytometry. A) Absolute number of G6PI-
specific (CD154
+) and G6PI-specific Th cells, expressing the indicated cytokine recovered from the draining lymph nodes of control or CD22-cal
treated animals (n=4 per group). B) Representative flow cytometry data from control (upper row) and CD22-cal treated (lower row) mice. Dot plots
B Cell Depletion in Experimental Arthritis
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e24718(11.663.2610
4 vs 1.660.3610
4; Fig. 6 A). This drastic reduction
was due to the combination of fewer lymph node cells in CD22-cal
treated animals (50.9610.5610
6 in control vs. 20.462.8610
6
cells) and the reduced frequency of G6PI-specific cells within this
reduced CD4
+ cell pool (0.2260.03 vs. 0.0860.01% of CD4
+
cells).
To assess the functional differentiation of the G6PI-specific Th
cells, we next investigated the expression of the effector cytokines
TNF-a, IL-17, RANKL, IFN-c and IL-2. Among the G6PI-
specific CD4
+ T cells the proportions of cells producing RANKL-
or IL-2 were similar in both groups of mice whereas the
percentages of G6PI-specific CD4
+ T cells that produced TNF-
a, IL-17 or IFN-c was higher in the CD22-cal treated mice than in
the controls (Fig. 6 B). Approximately 27% of CD154
+ cells from
the treated mice expressed TNF-a, compared with only ,20%
CD154
+ TNF-a producers in the control mice. Similarly, ,18%
of the G6PI-specific Th cells from the treated mice but only ,11%
from the control mice expressed IL-17 and for IFN-c these
percentages were ,11 and ,4, respectively (Fig. 6 B). Hence,
although the size of the G6PI-specific T cell compartment was
significantly reduced in CD22-cal-treated mice, within this
compartment the proportion of cells producing effector cytokines
was higher in the CD22-cal-treated mice than in controls.
Together, the drastically reduced size of the G6PI-specific T cell
compartment in combination with the higher frequency of
cytokine producing cells within this compartment still resulted in
a lower total number of cytokine secreting cells in CD22-cal
treated mice (compare Figs. 6 A and 6 B).
B-cell depletion results in impaired priming of G6PI-
specific Th cells in vivo
Assays of antigen-specific Th cell responses depend on intact
antigen-presentation during the brief ex vivo restimulation. Hence,
it is possible that the reduced number of G6PI-specific Th cells
response measured was not the consequence of disturbed in vivo
priming, but rather due to disturbed antigen-presentation caused
by a lack of B cells in our lymph node preparations from CD22-cal
treated mice. To control for that, we added CFSE-labeled
splenocytes from G6PI-immunized mice as additional APCs to
the lymph node cells and restimulated this mixed culture with
G6PI. CFSE-labeling of the splenocytes enabled us to identify
them and to gate them out during FACS-analysis. When we
analyzed these mixed cultures exactly as described above, we
found that the added APCs were not able to increase the number
of CD154
+ or cytokine producing cells in CD22-cal treated mice
(Fig. 6 C). This clearly demonstrates that the reduced number of
G6PI-specific T cells in these mice was truly due to a in vivo
priming defect and not to insufficient restimulation in the B cell
depleted lymph node cultures.
Discussion
Here report that in vivo depletion of B cells with CD22-cal
prevents but does not cure G6PI-induced arthritis. The ex vivo
correlates of protection were strongly reduced numbers of CD4
+
G6PI-specific Th cells and reduced serum-concentrations of
antibodies against G6PI.
Usually, DBA/1 mice are studied for G6PI-induced arthritis
[6,7,14,15,18,19]. The Cy34.1 antibody used in our current study
reacts with CD22 on strains expressing the Lyb-8.2 alloantigen,
which is not expressed in DBA/1 mice [13]. Therefore we
examined if Lyb-8.2
+ SJL/J mice were susceptible to G6PI-
induced arthritis. The incidence and severity of G6PI-induced
arthritis are similar in DBA/1 and SJL/J mice. Clinical signs of
arthritis appear slightly later in SJL/J than in DBA/1 mice and
G6PI-arthritis takes a more prolonged course in SJL/J mice. Thus,
we here demonstrate for the first time the susceptibility of SJL/J
mice for G6PI-induced arthritis.
Our finding that B cell depletion prevents G6PI-induced
arthritis when performed before immunization, ameliorates
arthritis when performed during the induction phase of the
disease and has no therapeutic effect when performed in already
arthritic mice extends earlier findings in other arthritis models. B
cell depletion using CD22-cal in ifng
2/2 C57BL/6 mice prevented
CIA [2]. Similarly, B cell depletion with an anti-murine CD20
mAb prevented CIA in DBA/1 mice but did not cure arthritic
mice [3]. B cell depletion with an anti-murine CD20 mAb reduced
only the severity but not the incidence of proteoglycan-induced
arthritis in BALB/c mice [4]. In contrast, B cell depletion with the
anti-human CD20 mAb Rituximab had no effect on arthritis in
hCD20tg K/BxN mice. Rituximab was administered when mice
were already arthritic and serum anti-G6PI IgG titers have
reached maximal levels [5]. Finally, transfer of splenocytes from
G6PI-immunized DBA/1 mice into SCID mice induced arthritis
the recipients whereas transfer of CD19
+-depleteds splenocytes did
not [18]. Taken together, the data obtained from different mouse
models of arthritis, using different strains of mice and different
approaches to B cell depletion uniformly show preventive but not
therapeutic efficacy.
These findings are in striking contrast to human RA where B
cell depletion with Rituximab produces long-lasting robust clinical
responses in many patients. Rituximab treatment does not affect
long-lived plasma cells, yet the serum concentrations of rheuma-
toid factors are reduced upon Rituximab treatment [20]. Perhaps
repeated T cell priming by B cells is necessary in RA but not in the
murine models of arthritis, which are induced upon immunization
with self-antigen in strong adjuvants?
B cells are important APC for CD4
+ Th cells, which are critical
for both the induction and the effector phase of G6PI-induced
arthritis [6]. Therefore, we analyzed the G6PI-specific Th cell
response in B cell depleted mice. T cell numbers were reduced in
the draining lymph nodes of CD22-cal treated mice after G6PI-
immunization although CD22-cal does not have a direct effect on
T cells [2]. CD4
+ T cells upregulate expression of CD154 rapidly
and transiently upon TCR stimulation. CD154 expression is
therefore highly indicative of antigen-specific CD4 T cell
stimulation during the 6 h of in vitro culture [14,16,21,
22,23,24]. We found a strikingly reduced number of G6PI-specific
Th cells in B cell depleted mice. The numbers of Th cells that
produced IFN-c, IL-17, RANKL, or TNF-a were also drastically
reduced. This deficiency could not be overcome by in vitro
stimulation with APC from syngenic mice that had not been
treated with CD22-cal. Thus, we show here for the first time that
T cell priming in vivo in the absence of B cells profoundly reduces
the number of autoantigen-specific effector Th cells. This is
supported by findings in the PGIA model where CD4
+ T cells
from B cell-depleted mice could not transfer disease into SCID
recipients [4]. T cell priming seems to depend on antigen
show expression of TNF-a (y-axis) against the other indicated cytokines by G6PI-specific (gated on CD154
+) Th cells. The data shown are the
concatenated data files from the 4 individual mice per group. C) Lymph node cells from the same mice as in A) and B) were stimulated in the
presence of CFSE-labeled splenic antigen-presenting cells and similarly analyzed after gating on the CFSE-negative population.
doi:10.1371/journal.pone.0024718.g006
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[3]. The prominent role of B cells as APCs especially for low-
abundant antigens might be explained by the fact that B cells very
efficiently take up and present antigens at much lower concentra-
tions than other APCs that sample antigens nonspecifically [3,25].
Autoantigens such as CII, PG or G6PI are present only in low
levels under normal circumstances. Thus, it is possible that after
initial DC-mediated triggering of an autoantigen-specific Th
response induced by immunization, the evolving B cell response
might become more and more important for subsequent
expansion and propagation of the specific Th cell response. Once
the T cell response is established, B cells become less important
which could explain the relatively small window of opportunity for
the protective effect of B cell depletion. In this scenario, the
reduced levels of autoantibodies could be interpreted as just an
indicator of this reduced T/B cell cooperation without any
significance for pathogenesis. The latter conclusion is, however,
unlikely given the therapeutic effect of in vivo cleavage of IgG2a in
CIA [26] or well-characterized protective effects of Fcc-receptor
blockade or complement deficiency [27,28,29,30]. We have
previously described a reduced severity of G6PI-induced arthritis
in mice deficient for the Fcc-receptor common c chain and an
exacerbated disease in mice lacking the inhibitory FccRIIB [6],
indicating the necessity for anti-G6PI Igs in the pathogenesis of
G6PI-induced arthritis.
Conclusions
In summary, our data show that B cell depletion is preventively
but not therapeutically effective in G6PI-induced arthritis. Clinical
signs of arthritis occur when B cells reappear in the blood and
antibody-titers reach levels similar to those in control mice. B cell
depletion results in a drastically reduced number of G6PI-specific
Th cells. Thus, B cells are critical for the pathogenesis of G6PI-
induced arthritis both as producers of antibodies and as APC for
the pathogenic Th cells.
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